

OCTREOTIDE

Reducing Polycystic Liver Volume Somatostatin Analogue Octreotide

Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P.

Clin J Am Soc Nephrol. 2010 Feb 25

<http://www.ncbi.nlm.nih.gov/pubmed/20185596>

CONCLUSIONS: Octreotide reduces liver volumes in patients

Octreotide is a long acting injection of somatostatin given every 28 days. It is currently in clinical trials for the treatment of PLD Polycystic Liver Disease. It reduces liver cysts and cystic liver size in the PLD animal model. A trial from the Netherlands showed at 5% - 33% reduction in polycystic livers in humans in a short term trial. In Italy, in a very small trial of 24, it was shown to reduce polycystic kidney size and polycystic liver size. There is an ongoing trial at the Mayo Clinic in Rochester Minnesota USA.

PHASE I YEARS 1 & 2

The second phase of the Octreotide study will be open to the original 42 participants who completed phase 1. Phase I is a two year study on octreotide. The first year was blinded; 60% received octreotide; 40% received placebo. I received placebo. The second year of Phase I study all received octreotide. This ended April 2010.

PHASE II YEARS 3 & 4

The second Phase of the octreotide study has begun. It is a bare bones shoe string study. Novartis will no longer pay for shipping of the drug. They will however provide octreotide injectable 28 day for all participants for full two years. The lab work must be covered by participants either through insurance or by self. The cost of once yearly blood work will be around \$410. Yearly MRI's will be covered by the study. Participants will need to return to the Mayo at the beginning; in one year and in two year's time. We can fax our 6 month lab work; or we can have it done before we arrive or we can have it done at the Mayo, whichever is convenient for participants.

The octreotide trial will no longer check kidney functioning.

[Reducing Polycystic Liver Volume in ADPKD: Effects of Somatostatin Analogue Octreotide.](#)

CONCLUSIONS: Octreotide therapy reduces liver volumes in patients with ADPKD and is safe.

[Effect of octreotide on polycystic liver volume.](#)

van Keimpema L, Drenth JP.

Liver Int. 2009 Sep 9. [Epub ahead of print] No abstract available.

[What the similarities of specific polycystic liver and kidney diseases can teach us about both.](#)

Hogan MC, Torres VE.

Nephrol News Issues. 2008 Aug;22(9):29-31. Review.

[Somatostatin analogues reduce liver volume in polycystic liver disease.](#)

van Keimpema L, de Man RA, Drenth JP.

Gut. 2008 Sep;57(9):1338-9.

[Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte](#)

Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF.

Gastroenterology. 2007 Mar;132(3):1104-16. Epub 2006 Dec 20.